1 Title: Syncytiotrophoblast extracellular vesicles contain functional kynurenine 2 metabolising enzymes: potential implications for preeclampsia. 3 Prassana Logenthiran^{1,2}, Toluwalase Awoyemi¹, Morganne Wilbourne¹, Zhanru Yu³, 4 Benedikt Kessler³, Carlos Escudero^{1,4}, Wei Zhang¹, Sofia Cerdeira¹, Manu Vatish^{1*} 5 6 ¹ Nuffield Department of Women's & Reproductive Health, University of Oxford, Women's 7 8 Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom 9 ² Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura, 10 Nugegoda, Sri Lanka 11 Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of 12 Medicine University of Oxford, Oxford OX3 7FZ, UK 13 ⁴ Vascular Physiology Laboratory, Group of Research and Innovation in Vascular Health, 14 Department of Basic Sciences, Universidad del Bío-Bío, Chillán, Chile. 15 Running title: Kynurenine is metabolized by syncytiotrophoblast extracellular vesicles. 16 17 18 *Correspondence: Manu Vatish University of Oxford 19 20 Nuffield Department of Women's & Reproductive Health 21 Level 3, Women's Centre 22 John Radcliffe Hospital 23 Oxford OX3 9DU 24 manu.vatish@wrh.ox.ac.uk

25

26 Abstract

Background: Placentae of women with preeclampsia (PE) exhibit reduced levels of kynurenine (Kyn), a biological compound derived from tryptophan metabolism with antioxidant, vasorelaxant, and hypotensive properties. Little is known regarding functional levels of the Kyn metabolizing enzymes (KYNME) in women with preeclampsia. Since high circulating levels of syncytiotrophoblast extracellular vesicles (STB-EVs) have been associated with preeclampsia onset, we aimed to study whether Kyn reduction in preeclampsia may be attributed to increased degradation by KYNME present in STB-EVs.

Methods: We conducted a study that included women with normal (n=9) and early-onset preeclamptic (EOPE) pregnancies (n=9). From them, STB-EVs were isolated by dual-lobe placental perfusions from normal (n=3) and EOPE (n=3). KYNME were identified using placental immunohistochemistry and western blot in placental and STB-EV extractions. Serum Kyn levels were measured using gas chromatography mass spectrometry.

39 **Results:** Cargo of STB-EVs consist of functional KYNME, which break down Kyn in a dose 40 and time-dependent manner. No significant differences in the content of Kyn metabolizing 41 enzymes were found in STB-EVs between normal and EOPE pregnancies. However, 42 decreased serum levels of Kyn were found in women with EOPE relative to normal 43 pregnancies. 44 **Conclusion:** STB-EVs carry functional KYNME and may regulate the levels of circulating 45 Kyn during normal pregnancy and preeclampsia. Due to the dose effect of increased STB-46 EVs in EOPE, the functional KYNME content of said vesicles may contribute to reduced 47 levels of Kyn. This finding opens a new avenue for investigating the potential benefits of 48 KYNME inhibitors in conjunction with kynurenine replacement for managing preeclampsia. 49 50 Key words: Extracellular vesicles; preeclampsia; Kynurenine; Tryptophan; Kynurenine 51 metabolising enzymes 52 Manuscript word count: 5992 53 Abstract word count: 250 54 **Financial disclosure:** The study was funded by internal contingency funds. 55 Conflict of interest: none 56 Number of figures: 5 57 Number of references: 43

58 **Keycode:** Placenta extracellular vesicles; normal pregnancy; preeclampsia.

59 Abbreviations: Chlorotrimethylsilane (TMCS). Comprehensive two-dimensional gas 60 chromatography (GCxGC-MS). Early-onset preeclampsia (EOPE). Extracellular vesicles 61 (EVs). Gas Chromatography Mass Spectrometry (GCMS). International Society for the Study 62 of Hypertension in Pregnancy (ISSHP). Kynureninase (Kynu). Kynurenine (Kyn). 63 Kynurenine aminotransferase III (KAT-III). Kynurenine monooxygenase (KMO). 64 Kynurenine metabolizing enzymes (KYNME). Medium/large syncytiotrophoblast 65 extracellular vesicles (m/lSTB-EVs). N-Methyl-N-trimethylsilyltrifluoroacetamide 66 (MSTFA). Nanoparticle tracking analysis (NTA). Normal pregnancy (NP). Placenta alkaline 67 phosphatase (PLAP). Placental indoleamine 2,3-dioxygenase (IDO). Preeclampsia (PE). 68 Small syncytiotrophoblast extracellular vesicles (sSTB-EVs). Syncytiotrophoblast (STB). 69 Syncytiotrophoblast extracellular vesicles (STB-EVs). Tryptophan (Trp)

70

72

73 Introduction

Preeclampsia (PE) is a multisystem disorder unique to human pregnancy affecting 2% - 8% of pregnancies worldwide^{1,2} and a leading cause of maternal morbidity and mortality^{3,4}. The International Society for the Study of Hypertension in Pregnancy (ISSHP) defines preeclampsia as, *de novo* hypertension (systolic blood pressure, SBP>140mmHg and diastolic blood pressure, DBP>90mmHg) with either new-onset proteinuria, or evidence of other maternal end-organ dysfunction (including liver, kidney, neurological); haematological involvement; or uteroplacental dysfunction⁵.

Preeclampsia is thought to originate because of poor placentation^{6,7}. In a pathophysiological context, the clinical syndrome is triggered by the release of placental pro-inflammatory, antiangiogenic, pro-coagulant factors, and syncytiotrophoblast extracellular vesicles (STB-EVs) as a response to syncytiotrophoblast (STB) stress. These biomolecules mediate maternal endothelial dysfunction, deranged angiogenic balance, vasoconstriction and resultant hypertension, and end organ damage^{6,8}.

87 The syncytiotrophoblast (the outer maternal facing membrane of the chorionic villus) is 88 known to release extracellular vesicles (STB-EVs) into the maternal circulation throughout pregnancy⁹. STB-EVs are membrane bound lipid particles that carry extravesicular proteins 89 90 and intra-vesicular cargo comprising of lipids, nucleic acids, and proteins, which may play an essential role in the physiological changes accompanying pregnancy¹⁰. STB-EVs are 91 92 classified based on their size; medium/large STB-EVs (m/lSTB-EVs) are 200 nm to 1 µm, and small STB-EVs (sSTB-EVs) are \sim 30-200 nm^{11,12}. m/ISTB-EVs are shed directly from the 93 94 STB layer via budding of the cell membrane in response to cell activation, cell stress or cell death¹³. In contrast, sSTB-EVs are released from intracellular multivesicular bodies of STB 95

96 by exocytosis, and they may play a key role in intercellular communication¹⁴. Importantly, 97 women with PE and specially those who present with early-onset PE (PE diagnosed before 34 98 weeks of gestation, EOPE) have shown high quantity of circulating STB-EVs compared with 99 normal pregnancy^{15,16}. Increasing evidence reports that STB-EVs may contribute to the 100 pathogenesis of PE by carrying pro and anti-angiogenic factors as cargoes^{17–19}.

101 Previous reports have suggested the potential beneficial effects of Kynurenine (Kyn), a 102 biologically active metabolite derived from Tryptophan (Trp) metabolism, in ameliorating detrimental consequences of PE²⁰. Kyn is found to be an antioxidant²¹ a vasorelaxant^{22,23}, and 103 104 a hypotensive agent²². Kyn has previously been reported to be reduced in placental explant 105 culture medium of PE compared to normal pregnancy $(NP)^{24}$. Recently, it has been shown 106 that replacing Kyn in pregnant mice with PE-like phenotype induced by uni-nephrectomy was sufficient to improve placental blood flow abnormalities and the PE-like phenotype^{25,26}. 107 108 These findings prompted the hypothesis that Kyn replacement may serve as a therapeutic 109 intervention to treat the clinical syndrome in PE^{25} .

110 Furthermore, Trp is metabolised by 4 different pathways (serotonin pathway, tryptamine 111 pathway, indole pyruvic acid pathway and kynurenine pathway), but the Kyn pathway accounts for ~95% of overall Trp degradation^{27,28}. The reduction in Kyn in PE was initially 112 113 attributed to reduced expression of indoleamine 2,3-dioxygenase (IDO) by the placenta, an enzyme responsible for breakdown of Trp to Kyn²⁹. However, the role of the Kyn 114 115 metabolising enzymes (KYNME)—Kynureninase (Kynu), Kynurenine aminotransferase III 116 (KAT-III) and Kynurenine monooxygenase (KMO)-responsible for breakdown Kyn has not been studied in PE³⁰. 117

118 We aimed to study whether STB-EVs carry functionally active KYNME and if Kyn119 reduction in PE may be attributed to increased degradation by KYNME on STB-EVs.

120

121 Methods

122 Human Subjects and Samples

123 The study received ethical approval from the Central Oxfordshire Research Ethics Committee 124 (RFS 07/H0607/74 & 07/H0606/148). Pregnant women who were scheduled to undergo an 125 elective caesarean section at the Women's Centre, John Radcliffe Hospital in Oxford, were 126 recruited for the study. Before the collection of placentae and blood, written informed 127 consent was obtained from all participants. EOPE was described as outlined above, and the 128 diagnosis was aided with an sFLT-1:PIGF ratio > 85 (n=9), while gestationally matched 129 women with normal pregnancies (NP) were selected based on no history of preeclampsia or hypertensive disorders and sFLT-1:PIGF ratio $< 38^{31}$. 130

Placentae were retrieved in the operating theatre and were perfused within 10 minutes (n=3 for both NP and EOPE). Blood samples were collected before caesarean section from NP (n=9) and EOPE (n=9) women in plastic serum tubes (BD Vacutainer, UK) from the left antecubital fossa. These blood samples were then centrifuged (Thermo Multifuge X3R) at a rate of 3,000 RPM for 10 minutes at a temperature of 21° C to separate the serum. The serum was then aliquoted and stored at a temperature of -80° C until analysis.

Placental biopsies were collected from the maternal facing surface (without the decidual
layer) for protein expression analysis. Placental lysates were prepared using RIPA buffer
(150 mM NaCl,50mM Tris pH 8.0, 0.1% SDS, 1% Triton X100, 0.5% sodium deoxycholate;
ThermoFisher Scientific, UK) and a protease inhibitor cocktail (Sigma Aldrich, UK) and
were subsequently subjected to a bicinchoninic acid (BCA) protein assay (Sigma Aldrich,
UK). The lysates were then stored at -20^oC until analysis.

143 Enrichment and Characterization of Syncytiotrophoblast Extracellular Vesicles (STB-

144 EVs)

145 STB-EVs were obtained from placentae using a modified ex-vivo dual lobe placental perfusion and differential ultracentrifugation method, as previously detailed by our group³²⁻ 146 147 ³⁵. Placentae were subjected to a 3-hour perfusion process, after which the maternal side perfusate was collected and promptly centrifuged twice using a Beckman Coulter Avanti J-148 149 20XP centrifuge and a Beckman Coulter JS-5.3 swing-out rotor. The centrifugation was performed at 1,500 \times g for 10 minutes at 4^oC to remove large cellular debris. The supernatant 150 151 was then collected and centrifuged again at $10,000 \times g$ for 35 minutes at 4^oC to pellet 152 m/ISTB-EVs. The m/ISTB-EVs were suspended in sterile PBS, and the remaining 153 supernatant was filtered through a 0.22 µm Stericup filter (Millipore, UK) and then centrifuged at 150,000 \times g for 125 minutes at 4^oC. This centrifugation was performed to pellet 154 155 sSTB-EVs. The sSTB-EVs were then re-suspended in sterile phosphate buffered saline 156 (PBS). The pellets containing m/ISTB-EVs and sSTB-EVs (from the 10K and 150K 157 centrifugations) were assessed for protein concentration using BCA protein assay kit (Sigma 158 Aldrich, UK).

159 Syncytiotrophoblast Extracellular Vesicles (STB-EV) characterization using 160 nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM) and 161 western blot

The NanoSight NS500 equipped with a sCMOS camera and NTA software 2.3, Build 0033 (Malvern Instruments, UK) was employed to evaluate the diameter and concentration of STB-EVs. The instrument was calibrated with silica 100 nm microspheres (Polysciences, UK). Following calibration, the size profile and concentration of STB-EVs were measured using a standard protocol described in earlier studies³².

In addition, sSTB-EVs were characterized by traditional immunoblotting using protein markers specific to sSTB-EVs, such as PLAP, a marker of syncytiotrophoblast origin, and well-known markers of exosomes, including Syntenin, Alix, CD63, and CD9, as recommended by the International Society for Extracellular Vesicles (ISEV). The results of this study confirm the origin of STB-EVs and their classification as exosomes (sSTB-EVs)³⁶.

172 Transmission electron microscopy (TEM)

173 STB-EV pellets were resuspended in phosphate-buffered saline (PBS) to achieve a final 174 concentration ranging from 0.1 to $0.3 \mu g/\mu l$. Suspension (10 μl) was applied to freshly glow-175 discharged carbon Formvar-coated 300 mesh copper grids. The grids were then negatively 176 stained with 2% uranyl acetate for 10 seconds, followed by blotting and air-drying. Imaging 177 was performed using a FEI Tecnai 12 TEM operating at an acceleration voltage of 120 kV. 178 Images were captured with a Gatan OneView CMOS camera.

179 Western blot

180 Immunoblotting was carried out under reducing conditions (except for CD63 performed in a 181 non-reducing condition) and denaturing conditions. Placental lysates (30 µg/well) and m/ISTB-EVs or sSTB-EVs (20 µg/well) were separated by electrophoresis on a 4%-12% 182 183 SDS-PAGE gel (Thermo Fisher, UK). The proteins were then transferred onto a PVDF 184 membrane (Bio-Rad Laboratories, UK) using a Novex Semi-Dry Blotter (Life Technologies, 185 Paisley, UK). The membranes were blocked for 1 hour at room temperature with 5% (w/v) 186 Blotto (Alpha Diagnostic, UK) in TBS-T (Tris-buffered saline solution with 0.1% Tween-187 20), and then incubated with primary antibodies, including anti-ALIX antibody ([1 mg/ml] at 188 1:1000 dilution, NBP1-49701, Novus Biologicals), anti-CD63 antibody ([200 µg/ml] at 189 1:1000 dilution, Sc-59286, Santa Cruz Biotechnology), anti-CD9 ([100 µg/ml] at 1:1000 190 dilution, Sc-59140, Santa Cruz Biotechnology), anti-cytochrome C ([200 µg/ml] at 1:1000

dilution, Sc-13156, Santa Cruz Biotechnology), and anti-PLAP ([1.67 µg/ml], at 1:1000
dilution, NDOG-2, in-house antibody), overnight at 4^oC. The membranes were washed using
TBS-T, and then incubated with horseradish peroxidase (HRP)-conjugated secondary
antibodies (Life Technologies, UK) in Blotto/0.1% TBS-T for 1 hour at room temperature.
Then, the antigen-antibody complexes were visualized by chemiluminescence using an ECL
kit (Thermo Scientific, UK).

197 Capillary Electrophoresis and Jess Simple Western

198 Diluted pooled STB-EVs (a mixture of m/ISTB-EVs and sSTB-EVs) obtained from NP (n=3) 199 and PE (n=3) placental perfusion, diluted liver cell lysate [Novus Biologicals, UK; (positive 200 control for KYNME)], and diluted placental tissue lysate (positive control for PLAP) were 201 combined with fluorescent master mix and heated at 95° C for 5 min. Protein samples, 202 blocking reagent, target primary antibody, secondary HRP (ready-to-use goat detection 203 module [Jess, Protein Simple], ready-to-use rabbit detection module [Jess, Protein Simple], 204 and ready-to-use mouse detection module [Jess, Protein Simple]), total protein detection 205 reagent, chemiluminescent substrate, and wash buffer were dispensed into designated wells in 206 the manufacturer-supplied microplate. Primary antibodies included goat anti-KYNU [R&D, 207 UK] diluted 1:10, rabbit anti-KMO [R&D, UK] diluted 1:10, rabbit anti-KAT-111 208 [MyBioSource, USA] diluted 1:10, and mouse anti-PLAP [NDOG2 in-house antibody] 209 diluted 1:50. The plate was then loaded into the instrument (Jess, Protein Simple) and 210 proteins were drawn into individual capillaries on a 13 / 25 capillary cassette (12-230 kDa). 211 Data were analysed using the proprietary Compass software provided by the manufacturer.

212 Immunohistochemistry

213 The placental tissues obtained from the biopsies were fixed in a solution of 4% formaldehyde 214 (v/v), embedded in paraffin blocks, and then sectioned at a thickness of 10 μ m. These

215 sections were placed on slides, and the slides were then processed for histological analysis. 216 Deparaffinized and rehydrated slides were subjected to heat treatment in a solution of 10 mM 217 sodium citrate at pH 6.0 for 10 minutes to facilitate antigen retrieval. Following this, the 218 slides were allowed to cool at room temperature. To block endogenous peroxidase activity, 219 the slides were treated with 3% (v/v) H_2O_2 in phosphate buffered saline (PBS). After that, 220 slides were blocked for non-specific antibody binding with 10% fetal calf serum (FCS) 221 (Sigma Aldrich, UK) in 0.01M PBS-T (PBS with Tween-20) (Sigma Aldrich, UK) at room 222 temperature (1 hour). Placental sections were incubated overnight at 4°C with 1% FCS and 223 respective target antibody, including either 1 µg/ml anti-Kynu primary antibody (OriGene, 224 USA); or 1 µg/ml anti-KATIII primary antibody (Santa Cruz Biotechnology, USA); or 1 225 µg/ml anti-KMO primary antibody (MyBioSource, USA) or non-immune mouse IgG1 226 (Biolegend, UK) in PBS-T. The sections were then washed and incubated with α anti-mouse 227 IgG secondary antibody conjugated to horseradish peroxidase (HRP) (Life Technologies, 228 UK) in 10% v/v FCS for 1 hour at room temperature. The slides were then rinsed with PBS-T 229 and stained with DAB (Vector Laboratories, USA). Afterward, hematoxylin solution 230 (Thermo Fisher, UK) was used to stain cell's nucleus. The slides were then observed under a 231 Leica DMIRE 2 microscope. Images were captured using Hamamatsu Orca digital camera 232 and HCI software.

233 Gas Chromatography Mass Spectrometry (GCMS)

234 Sample preparation.

Extraction of metabolites was carried out at room temperature if not indicated otherwise. 800 μ L of extraction solvent isopropanol (IPA) [1 % trifluoroacetic acid (TFA)] and 2.5 μ L myristic acid-14,14,14-d3 in IPA (1 mg/mL) were added into a bead beater tube with 100 μ L of sample. The mixtures were subsequently homogenized in a bead beater (Precellys 24,

Bertin Technologies) for three cycles (5000 rpm x 20 s) with dry ice bath between the cycles. Then the mixtures were kept at -80° C for 60 min and were centrifuged (20 min at 13,000g at 4°C). The supernatant (aqueous) was collected and transferred into the glass vial to dry under vacuum (Speedvac) overnight.

243 Chemical derivatization

Chemical derivatization was performed as previously described³⁷. In brief, samples were resuspended in a mixture of 50 μ L N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) with 1% chlorotrimethylsilane (TMCS) and 50 μ L pyridine. The mixture was then incubated for one hour at 60^oC at a shaking speed of 1200 rpm. After incubation, the samples were cooled to room temperature and injected directly for gas chromatography-mass spectrometry (GC-MS) analysis.

250 Comprehensive two-dimensional gas chromatography (GCxGC-MS) analysis

251 The samples were promptly analyzed using a GCxGC-MS system, which comprised a gas 252 chromatograph coupled to a quadrupole mass spectrometer (Shimadzu GCMS QP2010 Ultra) and a Shimadzu AOC-20i/s auto sampler, as described previously³⁸. The first-dimension 253 254 separation was performed on a SHM5MS capillary column (30 m \times 0.25 mm i.d. \times 0.25 μ m 255 film thickness, Shimadzu, Japan). The second-dimension separation was carried out on a 256 BPX-50 capillary column (5 m \times 0.15 mm i.d. \times 0.15 μ m film thickness, SGE, USA). Helium 257 gas was employed as a carrier gas at a constant inlet head pressure of 73 psi. The modulation period was set to 4 seconds. The samples were injected at a temperature of 280^oC in different 258 259 split ratios of 1:1 or 1:10. The oven temperature was programmed to commence at 100^oC and 260 hold for 2 minutes, before increasing to 220° C at a rate of 30° C per minute and holding for an 261 additional minute. The temperature was then raised to 280°C at a rate of 5°C per minute, held 262 for 1 minute, and finally increased to 300° C, where it was held for 2 minutes. The interface

263	temperature between the mass spectrometer and the oven was set at 300° C, while the ion
264	source was heated to 230°C. The mass spectrometer was operated at scan speeds ranging
265	from 5,000 to 20,000 amu, covering a mass range of 45-600 m/z. Electron Ionization spectra
266	were recorded at an energy of 70 eV.

267 Data processing and analysis

- 268 Raw GCxGC MS data were processed using GCMS solution software (version 2.72/4.20,
- 269 Shimadzu), and Chromsquare software (version 2.1.6, Shimadzu) in combination with GC
- 270 Image (version 2.3) and the NIST 11/s, OA_TMS, FA_ME, and YUTDI in-house libraries
- 271 were used for data analysis. The annotation of kynurenine was carried out by comparing them
- to external standards, which included IM spectra and retention times adjusted to the internal
- standard myristic acid-14,14,14-d3. The quantitation of kynurenine was measured using the
- 274 GCMS Solution software (version 4.2) as accumulated single ion monitoring (m/z 307).

275 Statistics

Graphs were created, and statistical analyses were conducted using GraphPad Prism (GraphPad Software V10.2.2, Boston, MA, USA). Comparison between the two groups was assessed using Student's paired/unpaired t-test, with a confidence interval of 95%. A *p*-value of <0.05 was considered statistically significant.

280 Results

281 Demographics and clinical characteristics

Table 1 illustrates the demographic characteristics of the women who were studied. As anticipated, women who experienced EOPE displayed significantly higher systolic and diastolic blood pressure, but lower gestational age at delivery, associated with lower birth

weight than women with NP (p<0.0001 in all cases). Additionally, the sFlt-1:PlGF ratio was higher in EOPE than NP women (599.3 vs 1.0) (p<0.05). However, no significant differences were observed in maternal age, body mass index (BMI), or gestational age at which blood samples were collected.

STB-EVs characterisation by nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM) and western blot (WB)

The results of the NTA revealed that the m/ISTB-EVs extracted from NP placentas were characterized by heterogeneity, with a modal size of 250.8 ± 26.1 nm (Figure 1A). In contrast, the sSTB-EVs exhibited less heterogenic size distribution with a modal size of 169.2 ± 8.7 nm (Figure 1B).

TEM showed the typical cup-shaped morphology of extracellular vesicles. The 10K STB-EV pellet showed a size heterogeneity characteristic of m/ISTB-EVs (200 to 1000nm) while the 150K STB-EV pellet showed a homogeneous EV size profile (less than or equal to 200 nm) (Figure 1A, 1B).

The western blot analysis confirmed that both types of EVs expressed the classic STB membrane marker, PLAP, and sSTB-EVs were particularly enriched for ALIX, CD9, and CD63. Furthermore, the results indicated that the m/ISTB-EVs and sSTB-EVs correctly lacked the negative EV marker cytochrome C (Figure 1C).

303 KYNME expression in placental tissues

Western blot analysis of whole placental lysates obtained from NP (n=3) and EOPE (n=3) exhibited the expression of KYNME including kynureninase (KYNU, 54 kDa), kynurenine monooxygenase (KMO, 59 kDa), and kynurenine aminotransferase III (KAT-III, 59 kDa)

307 (Figure 2A). Liver cell lysate served as the positive control for KYNME. The immunoblot
308 was also probed for PLAP (~66 kDa) to confirm the placental origin of the samples (Figure
309 2A). Qualitative estimation of KYNME found no change between NP and EOPE placental
310 extractions.

311 Additionally, immunohistochemistry was used to confirm the expression of KYNME in the

312 placenta, and the stromal-vascular bed (STB layer) exhibited intense KYNME staining in

both EOPE and NP placental tissues (Figure 2B). Again, qualitative estimation of KYNME in

the placental immunodetection showed no differences between NP and EOPE.

315 KYNME expression in STB-EVs

316 We sought to identify KYNME expression in pooled STB-EVs (mixture of m/ISTB-EVs and 317 sSTB-EVs) obtained from ex-vivo dual lobe placental perfusion of NP (n=3) and EOPE 318 (n=3) using capillary electrophoresis and western blot. Liver cell lysate and placental lysate 319 were used as the positive controls for KYNME and PLAP, respectively. Surprisingly, all 320 samples (NP and EOPE) tested positive for all three KYNME markers (KYNU, KMO, and 321 KAT-III) and co-expressed PLAP (see Figure 3A). Simultaneous total protein analysis was 322 conducted to ensure accurate results, and the Compass software was utilized to analyze the 323 normalized observed band densities. The variations in KYNME expression between NP and 324 EOPE samples were not statistically significant (see Figure 3B).

325 Functional assessment of KYNME expressed in STB-EVs

We sought to investigate the functional capacity of the KYNME expressed in STB-EVs (Fig 4) by measuring levels of kynurenine using GCxGC-MS. Kynurenine solution was treated with varying amounts of STB-EVs (1 μ g and 5 μ g of total protein) and two different

incubation periods (5 min and 60 min). As a control, the kynurenine solution was incubated

- 330 with STB-EVs treated with 100% trifluoroacetic acid to denature the protein cargo.
- 331 The results showed that both 1 μ g and 5 μ g of STB-EVs reduced the kynurenine levels by
- $\sim 80\%$ and $\sim 90\%$ respectively, compared to the control condition, (p < 0.05 for both 1 µg and
- 5 μg)). Moreover, STB-EVs demonstrated a dose-dependent breakdown of kynurenine, as
- evidenced by the significant reduction in kynurenine levels when 5 μ g of STB-EVs was used
- compared to 1 μ g, in both incubation periods (*p*<0.05 in both cases).

336 Measurement of serum kynurenine

337 Using GCxGC-MS, we investigated the serum levels of kynurenine in women with EOPE

338 (sFLT-1:PIGF ratio > 85) (n=9) and gestationally matched women with NP (sFLT-1:PIGF

ratio < 38) (n=9) (Fig 5). Women with EOPE exhibited significantly lower levels of

kynurenine compared with NP women (p < 0.05) (Fig 5B).

341 **Discussion**

342 In this study, we describe for the first time that STB-EVs cargo includes functional 343 kynurenine metabolising enzymes (KYNU, KMO and KAT-III). These enzymes breakdown 344 kynurenine, a biologically active metabolite known for its antioxidant, vasodilatory and 345 hypotensive effects. Despite no significant differences in the content of kynurenine 346 metabolising enzymes being found between NP and EOPE STB-EVs, serum levels of 347 kynurenine were significantly reduced in EOPE. While other possible causes of this 348 discrepancy must be considered, these findings suggest that STB-EVs may participate in the 349 regulation of circulating kynurenine levels in NP and EOPE. This is particularly true given 350 that circulating levels of STB-EVs are higher in EOPE^{15,16}. This dose effect may lead to 351 higher concentrations of kynurenine metabolising enzymes and subsequently to reduced

levels of kynurenine. Whether STB-EV-mediated kynurenine metabolism participates in the
cascade of placental, angiogenic or immunological defects observed in PE requires further
investigation.

355 During normal pregnancy, tryptophan metabolism to kynurenine is increased due to the 356 upregulation of placental indoleamine 2,3-dioxygenase (IDO) expression³⁹, which may play a critical role in mediating immune tolerance^{40,41} and vascular remodelling in the maternal-357 foetal interface^{42,43}. In PE placental culture, the culture media have been found to have 358 359 reduced kynurenine levels, which has been attributed to the reduced expression of the IDO 360 enzyme in the PE placenta²⁴. Based on existing literature, we hypothesized that STB-EVs 361 express functionally active KYNME in addition to placental expression. Since the STB layer 362 of the placenta is known to extrude extracellular vesicles into the circulation, we believe that 363 the enzymes expressed on the STB-EVs could scavenge circulating kynurenine and reduce 364 the levels of available circulating kynurenine.

365 Our study provided evidence of the presence of KYNME in the placental tissue through 366 immunohistochemistry and western blot in both NP and PE placentae. The 367 immunohistochemistry staining intensity was highest in the STB layer in both NP and EOPE 368 placentae. We discovered that KYNME was expressed in STB-EVs obtained from NP and 369 EOPE placental perfusions, and the expression levels were similar. However, previous 370 research by our group showed that PE placentae release significantly more STB-EVs per unit 371 of blood than NP¹⁶. Therefore, it is possible that the quantity of STB-EV carried KYNME per 372 unit of blood is also higher in PE than in NP. This hypothesis is at least partly supported by 373 our findings, which showed that kynurenine levels were significantly reduced when exposed 374 to a higher quantity of STB-EVs (carrying functional KYNME) derived from NP implying a 375 dose response relationship between STB-EVs and kynurenine levels. Furthermore, we

validated our findings by observing a significant reduction in serum kynurenine levels in
biochemically and clinically confirmed EOPE women compared to gestationally matched
controls.

379 Recent research has demonstrated that kynurenine replacement was effective in reversing 380 abnormal placentation and reducing the likelihood of developing PE in uni-nephrectomised 381 mice²⁵. Our research presents a novel approach to investigate the function of STB-EVs from 382 NP and PE in regulating kynurenine metabolism. For example, our findings indicate that 383 exposing kynurenine to STB-EVs denatured using 100% trifluoracetic acid (TFA) results in 384 significantly higher levels of kynurenine. This opens the possibility of exploring the use of 385 specific inhibitors for individual kynurenine metabolizing enzymes to mitigate the breakdown 386 of kynurenine.

Despite the relevance of our findings, we acknowledge limitations in our study including the small sample size in our analysis. In this study, we used relatively stringent criteria to define EOPE, which was aimed to generate as homogenous a disease pathophysiology as is possible in this complex condition. Recruitment was difficult with a distinct phenotype from its late onset component (LOPE), not only due to clinical complications which are sometimes emergent, but the relative rarity of EOPE in our institution, as it is in other institutions from high income countries.

In conclusion, our research unveils functional KYNME expression in STB-EVs from NP and PE patients, offering new insights into the clinical syndrome of preeclampsia. Our findings raise important questions about the potential effectiveness of kynurenine replacement as a strategy for managing preeclampsia and suggest that further investigation is needed to explore the role of KYNME inhibitors in conjunction with kynurenine replacement as a better alternative for managing the condition.

400 Clinical perspective

401 This study presents the first evidence of functional kynurenine metabolizing enzymes 402 (KYNME) associated with circulating syncytiotrophoblast-derived extracellular vesicles 403 (STB-EVs). Previous work by our group has shown that syncytiotrophoblasts in EOPE patients shed a greater number of EVs^{15,16}, which translates to an increased concentration of 404 405 circulating KYNME per unit blood volume. This may potentially explain in part the observed 406 reduction in serum kynurenine levels in EOPE. Based on these findings, future research 407 should explore the therapeutic potential of co-administering specific KYNME inhibitors with 408 kynurenine replacement therapy to effectively elevate circulating kynurenine levels in EOPE 409 patients.

Furthermore, our in vitro data reveals a dose- and time-dependent breakdown of kynurenine by STB-EVs. This opens a promising new avenue for the development of sensitive and specific tools for detecting kynurenine metabolites as potential biomarkers of EOPE. Future research efforts should explore the feasibility of utilizing these metabolites for early diagnosis and disease monitoring in EOPE patients.

415 **Conflict of interest**

416 None to declare.

417 Author contribution

418 MV conceptualized the study and lead the research team. PL performed most of the 419 experiments in this manuscript. TA, MW, ZY and WZ performed selected experiments. SC 420 and MV were responsible for patient recruitment. PL, TA, BK, CE, WZ and MV edited the 421 manuscript. BK, SC and MV supervised the project. All co-authors approved the final version 422 of this manuscript.

423 Acknowledgements

- 424 We acknowledge senior research midwife Fenella Roseman and research midwife Lotoyah
- 425 Carty who kindly recruited the patients for the study.

426 **References**

- Duley L. The Global Impact of Pre-eclampsia and Eclampsia. *Semin Perinatol.* 2009;33(3):130-137. doi:10.1053/j.semperi.2009.02.010
- 429 2. Hypertension in Pregnancy. *Obstetrics & Gynecology*. 2013;122(5):1122-1131.
 430 doi:10.1097/01.AOG.0000437382.03963.88
- 431 3. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of
 432 preeclampsia: A hypothesis and its implications. *Am J Obstet Gynecol*.
 433 1996;175(5):1365-1370. doi:10.1016/S0002-9378(96)70056-X
- 434 4. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *The Lancet*.
 435 2010;376(9741):631-644. doi:10.1016/S0140-6736(10)60279-6
- Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy:
 ISSHP classification, diagnosis & management recommendations for international
 practice. *Pregnancy Hypertens*. 2018;13. doi:10.1016/j.preghy.2018.05.004
- 439 6. Redman CWG, Sacks GP, Sargent IL. Preeclampsia: An excessive maternal
 440 inflammatory response to pregnancy. *Am J Obstet Gynecol*. 1999;180(2):499-506.
 441 doi:10.1016/S0002-9378(99)70239-5
- Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: Making sense of preeclampsia Two placental causes of preeclampsia? *Placenta*. 2014;35.
 doi:10.1016/j.placenta.2013.12.008
- Redman CWG, Staff AC, Roberts JM. Syncytiotrophoblast stress in preeclampsia: the
 convergence point for multiple pathways. *Am J Obstet Gynecol*. 2022;226(2):S907S927. doi:10.1016/j.ajog.2020.09.047
- 448 9. Awoyemi T, Cerdeira AS, Zhang W, et al. Preeclampsia and syncytiotrophoblast
 449 membrane extracellular vesicles (STB-EVs). *Clin Sci.* 2022;136(24):1793-1807.
 450 doi:10.1042/CS20220149
- 451 10. Baig S, Kothandaraman N, Manikandan J, et al. Proteomic analysis of human placental
 452 syncytiotrophoblast microvesicles in preeclampsia. *Clin Proteomics*. 2014;11(1):40.
 453 doi:10.1186/1559-0275-11-40
- 454 11. Dragovic RA, Collett GP, Hole P, et al. Isolation of syncytiotrophoblast microvesicles
 455 and exosomes and their characterisation by multicolour flow cytometry and
 456 fluorescence Nanoparticle Tracking Analysis. *Methods*. 2015;87:64-74.
 457 doi:10.1016/j.ymeth.2015.03.028
- 458 12. Awoyemi T, Motta-Mejia C, Zhang W, et al. Syncytiotrophoblast Extracellular
 459 Vesicles From Late-Onset Preeclampsia Placentae Suppress Pro-Inflammatory

460 Immune Response in THP-1 Macrophages. Front Immunol. 2021;12. 461 doi:10.3389/fimmu.2021.676056 462 13. Lv Y, Tan J, Miao Y, Zhang Q. The role of microvesicles and its active molecules in 463 regulating cellular biology. JCell Mol Med. 2019;23(12):7894-7904. doi:10.1111/jcmm.14667 464 465 14. Théry C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol 466 Rep. 2011;3. doi:10.3410/B3-15 467 15. Knight M, Redman CWG, Linton EA, Sargent IL. Shedding of syncytiotrophoblast 468 microvilli into the maternal circulation in pre-eclamptic pregnancies. BJOG. 469 1998;105(6):632-640. doi:10.1111/j.1471-0528.1998.tb10178.x 470 16. Goswami D, Tannetta DS, Magee LA, et al. Excess syncytiotrophoblast microparticle 471 shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine 472 growth restriction. Placenta. 2006;27(1). doi:10.1016/j.placenta.2004.11.007 473 Gardiner C, Tannetta DS, Simms CA, Harrison P, Redman CWG, Sargent IL. 17. 474 Syncytiotrophoblast Microvesicles Released from Pre-Eclampsia Placentae Exhibit 475 Increased Tissue Factor Activity. PLoS One. 2011;6(10):e26313. 476 doi:10.1371/journal.pone.0026313 477 18. Ribeiro MF, Zhu H, Millard RW, Fan GC. Exosomes Function in Pro- and Anti-478 Angiogenesis. Curr Angiogenes. 2013;2(1):54-59. 479 doi:10.2174/22115528113020020001 480 19. Guller S, Tang Z, Ma YY, Di Santo S, Sager R, Schneider H. Protein composition of 481 microparticles shed from human placenta during placental perfusion: Potential role in 482 and fibrinolysis in preeclampsia. *Placenta*. angiogenesis 2011;32(1):63-69. 483 doi:10.1016/j.placenta.2010.10.011 484 20. Worton SA, Pritchard HAT, Greenwood SL, et al. Kynurenine Relaxes Arteries of 485 Normotensive Women and Those With Preeclampsia. Circ Res. 2021;128(11):1679-486 1693. doi:10.1161/CIRCRESAHA.120.317612 487 Rios C, Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain 21. 488 homogenates. Neurochem Res. 1991;16(10). doi:10.1007/BF00966592 489 22. Wang Y, Liu H, McKenzie G, et al. Kynurenine is an endothelium-derived relaxing 490 factor produced during inflammation. Nat Med. 2010;16(3). doi:10.1038/nm.2092 491 23. Sakakibara K, Feng GG, Li J, et al. Kynurenine causes vasodilation and hypotension 492 induced by activation of KCNQ-encoded voltage-dependent K+ channels. J 493 *Pharmacol Sci.* 2015;129(1). doi:10.1016/j.jphs.2015.07.042 494 24. Dunn WB, Brown M, Worton SA, et al. Changes in the Metabolic Footprint of 495 Placental Explant-Conditioned Culture Medium Identifies Metabolic Disturbances 496 Related to Hypoxia and 2009;30(11). Pre-Eclampsia. Placenta. 497 doi:10.1016/j.placenta.2009.08.008 498 25. Dupont V, Berg AH, Yamashita M, et al. Impaired renal reserve contributes to 499 preeclampsia via the kynurenine and soluble fms-like tyrosine kinase 1 pathway. 500 of Clinical Investigation. Published online August Journal 9, 2022. 501 doi:10.1172/JCI158346

- Levine RJ, Maynard SE, Qian C, et al. Circulating Angiogenic Factors and the Risk of
 Preeclampsia. *New England Journal of Medicine*. 2004;350(7).
 doi:10.1056/NEJMoa031884
- 505 27. Bender DA. Biochemistry of tryptophan in health and disease. *Mol Aspects Med.*506 1983;6(2):101-197. doi:10.1016/0098-2997(83)90005-5
- 507 28. Badawy AAB. Tryptophan Metabolism in Alcoholism. In: ; 1999:265-274.
 508 doi:10.1007/978-1-4615-4709-9_33
- 509 29. Kudo Y, Boyd CAR, Sargent IL, Redman CWG. Decreased tryptophan catabolism by
 510 placental indoleamine 2,3-dioxygenase in preeclampsia. *Am J Obstet Gynecol.*511 2003;188(3). doi:10.1067/mob.2003.156
- 512 30. Badawy AAB. Kynurenine pathway of tryptophan metabolism: Regulatory and
 513 functional aspects. *International Journal of Tryptophan Research*. 2017;10(1).
 514 doi:10.1177/1178646917691938
- 515 31. Cerdeira AS, O'Sullivan J, Ohuma EO, et al. Randomized Interventional Study on
 516 Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia.
 517 Hypertension. 2019;74(4). doi:10.1161/HYPERTENSIONAHA.119.12739
- 518 32. Dragovic RA, Collett GP, Hole P, et al. Isolation of syncytiotrophoblast microvesicles
 519 and exosomes and their characterisation by multicolour flow cytometry and
 520 fluorescence Nanoparticle Tracking Analysis. *Methods*. 2015;87:64-74.
 521 doi:10.1016/j.ymeth.2015.03.028
- Jiang S, Zhang W, Cao Q, et al. ExoCounter Assays Identify Women Who May
 Develop Early-Onset Preeclampsia From 12.5 μL First-Trimester Serum by
 Characterizing Placental Small Extracellular Vesicles. *Hypertension*. 2023;80(7):14391451. doi:10.1161/HYPERTENSIONAHA.123.20907
- 34. Awoyemi T, Jiang S, Rahbar M, et al. MicroRNA analysis of medium/large placenta
 extracellular vesicles in normal and preeclampsia pregnancies. *Front Cardiovasc Med.*2024;11. doi:10.3389/fcvm.2024.1371168
- 35. Awoyemi T, Zhang W, Rahbar M, et al. A cross-sectional analysis of syncytiotrophoblast membrane extracellular vesicles-derived transcriptomic biomarkers in early-onset preeclampsia. *Front Cardiovasc Med.* 2023;10.
 doi:10.3389/fcvm.2023.1291642
- 533 36. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of
 extracellular vesicles 2018 (MISEV2018): a position statement of the International
 Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J *Extracell Vesicles*. 2018;7(1):1535750. doi:10.1080/20013078.2018.1535750
- 537 37. Yu Z, Huang H, Zhang H, Kessler BM. Improved profiling of polyamines using two538 dimensional gas chromatography mass spectrometry. *Talanta*. 2019;199:184-188.
 539 doi:10.1016/j.talanta.2019.02.062
- S40 38. Yu Z, Huang H, Reim A, et al. Optimizing 2D gas chromatography mass spectrometry
 for robust tissue, serum and urine metabolite profiling. *Talanta*. 2017;165:685-691.
 doi:10.1016/j.talanta.2017.01.003
- 39. Broekhuizen M, Danser AHJ, Reiss IKM, Merkus D. The Function of the Kynurenine
 Pathway in the Placenta: A Novel Pharmacotherapeutic Target? *Int J Environ Res Public Health*. 2021;18(21):11545. doi:10.3390/ijerph182111545

54640.Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by547tryptophan catabolism.Science.548doi:10.1126/science.281.5380.1191

- 41. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition
 of T Cell Proliferation by Macrophage Tryptophan Catabolism. *J Exp Med.*1999;189(9):1363-1372. doi:10.1084/jem.189.9.1363
- 42. Zardoya-Laguardia P, Blaschitz A, Hirschmugl B, et al. Endothelial indoleamine 2,3dioxygenase-1 regulates the placental vascular tone and is deficient in intrauterine
 growth restriction and pre-eclampsia. *Sci Rep.* 2018;8(1):5488. doi:10.1038/s41598018-23896-0
- Broekhuizen M, Klein T, Hitzerd E, et al. Tryptophan–Induced Vasodilation Is
 Enhanced in Preeclampsia. *Hypertension*. 2020;76(1):184-194.
 doi:10.1161/HYPERTENSIONAHA.120.14970

559

560 Table legend

561 Table 1. Clinical characteristics of studied women.

Note: Values presented as mean \pm SD. SBP, systolic blood pressure. DPB, diastolic blood pressure. BMI, body mass index (kg/m²).

564

565 Figure legend.

566 Figure 1. Characterization of large/medium and small STB-EVs isolated from normal 567 pregnancies. A) Representative characterization of medium/large STB-EVs, and B) small 568 STB-EVs by NTA. Inserted images are representative pictures of respective STB-EVs 569 characterized by TEM. Right, scale bar = 1000 nm. Left, scale bar = $2 \mu m$. White square 570 represent section amplified. N=3 per group. C) Representative images of Western blot for 571 detecting placental origin of STB-EVs. Placental alkaline phosphatase (PLAP) was used as 572 placental marker. CD63, CD9 and Alix were used as positive marker of EVs. Cytochrome C 573 (CYT.C) was used as negative marker of EVs.

574

575 Figure 2. Placental protein expression of kynurenine metabolising enzymes (KYNME).

576 A) Placental lysates obtained from normal pregnancy (NP, n=3) and preeclamptic

577 pregnancies (EOPE, n=3) probed for KYNME and placental alkaline phosphatase (PLAP).

578 HEPG2 cell lysate used as positive control. **B**) Immunohistochemistry analysis of placental

- 579 expression of Anti KYNU (1); Anti KAT III (2) and Anti KMO (3) in NP and EOPE
- 580 placentas. Arrows indicate presence of these proteins in the syncytiotrophoblast cells.

581

582 Figure 3. KYNMEs are expressed by STB-EVs isolated from normal and preeclamptic

pregnancies. A) Representative images of capillary electrophoresis of KYNME including KYNU, KMO, and KAT-III in STB-EVs extracted from normal (NP, n=3) and preeclamptic pregnancies (EOPE, n=3). Placental alkaline phosphatase (PLAP) was used as placental marker. Liver cell and placental lysates were used as respective positive and negative controls. **B**) Relative values of KYNMEs after normalizing for total protein. NS, nonstatistical significance. Values are presented as mean \pm SD.

589

590 Figure 4. STB-EVs isolated from normal pregnancy break down kynurenine. A)

591 Percentage of kynurenine metabolized with STB-EVs (1 μ g, red bar; and 5 μ g, green bar, of

total protein) isolated from normal pregnancy placentae (n=3). Two different incubation time

were tested. **B**) 5 min, and **C**) 60 min of incubation with STB-EVs. Denatured STB-EVs

594 (using 100% trifluoracetic acid) were used as control. Each dot represents an individual STB-

EV extraction. Values are presented as mean \pm SD. *p* value is indicated in each comparison.

596

Figure 5. Serum kynurenine levels in normal and preeclamptic pregnancies. A) Representative chart of gas chromatography mass spectrometry for kynurenine (KYN) detection in serum from normal (NP, n=9, pink) and preeclamptic pregnancies (EOPE, n=9, blue). As a control we used an in-house library of KYN (black). B) Amplification of the chromatogram in which KYN is detected. Notice the differences in the peak generated in NP and EOPE samples. C) KYN levels presented as mean \pm SD. Each dot represents an individual. *p* value is indicated in each comparison.

Medium/Large STB-EVs









В





С

PL M/L S M/L S M/L S PL



PLAP ~66kDa

CD63 ~30-65kDa

CD9 ~25kDa

ALIX ~95kDa

CYT.C ~12kDa

medRxiv preprint doi: https://doi.org/10.1101/2024.05.25.24307626; this version posted May 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



LC NP NP NP PE PE PE



medRxiv preprint doi: https://doi.org/10.1101/2024.05.25.24307626; this version posted May 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



PLAP ~66kDa

KYNU ~54kDa

KAT-III ~59kDa

KAT-III

B

Σ Σ





NP













	NP (n=9)	EOPE (n=9)	P value
Age (years)	28.6 ± 4.2	30.4 ± 4.1	> 0.05
Gestational age (weeks)	28.3 ± 2.9	28.0 ± 2.7	> 0.05
SBP (mmHg)	111.3 ± 7.5	156.3 ± 14.6	< 0.0001
DBP (mmHg)	67.3 ± 6.1	100.8 ± 6.6	< 0.0001
BMI (kg/m²)	24.2 ± 4.0	29.1 ± 7.6	> 0.05
Birth weight (g)	3801 ± 666.3	1815 ± 527.5	< 0.0001
Gestation at delivery (weeks)	39.0 ± 1.3	32.3 ± 2.7	< 0.0001
sFlt-1:PlGF	1.0 ± 0.2	599.3 ± 569.5	< 0.05

Table 1. Clinical characteristics of studied women.

Note: Values are presented mean \pm SD. SBP, systolic blood pressure. DPB, diastolic blood pressure. BMI, body mass index (kg/m²).